An Open Label Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BAY 1841788 in Japanese Subjects With Metastatic Castration-resistant Prostate Cancer

Trial Profile

An Open Label Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BAY 1841788 in Japanese Subjects With Metastatic Castration-resistant Prostate Cancer

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Darolutamide (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Bayer; Bayer Yakuhin
  • Most Recent Events

    • 01 Dec 2017 Results published in the Cancer Chemotherapy and Pharmacology Journal.
    • 14 Oct 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
    • 16 Mar 2015 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top